Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Ustekinumab
Treatment for Psoriasis
Typical Dosage: 45mg or 90mg SC at weeks 0, 4, then every 12 weeks
Effectiveness
80%
Safety Score
57%
Clinical Trials
94
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
57
DangerousModerateSafe
Treatment Details
Dosage Range
45mg or 90mg SC at weeks 0, 4, then every 12 weeks
Time to Effect
4-12 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
2.5(Treat 2.5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
100(Treat 100 patients to see 1 additional serious adverse event)
Confidence Score
96%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$90,000
Monitoring:$600
Side Effect Mgmt:$500
Total Annual:$91,100
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$35,000/QALY
QALYs Gained
1.2
Outcome-Based Costs
Cost per Responder
$135,970
Cost per Remission
$364,400
Ustekinumab Outcomes
for Psoriasis
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+67%
Remission Rate
+25%
Common Side Effects
Nasopharyngitis
+11.2%
Upper respiratory tract infection
+9.8%
Headache
+8.7%
Injection site erythema
+5.1%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
3 active trials recruiting for Ustekinumab in Psoriasis
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
NCT05270733RECRUITINGPHASE4
56 participants
INTERVENTIONAL
Cleveland, United States
Started: Nov 10, 2022
A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis
NCT03218488ACTIVE NOT RECRUITING
135 participants
OBSERVATIONAL
Graz, Austria +29 more
Started: Oct 25, 2017
An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis
NCT06488664ACTIVE NOT RECRUITINGPHASE3
422 participants
INTERVENTIONAL
Barnaul, Russia +33 more
Started: Jul 25, 2023
Completed Clinical Trials
16 completed trials for Ustekinumab in Psoriasis
Bioequivalence Phase I Study of BFI-751 Compared With EU and US-STELARA® in Healthy Adults
NCT04843631COMPLETEDPHASE1
216 participants
INTERVENTIONAL
Brisbane, Australia +2 more
Started: Apr 1, 2021
An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis
NCT00454584COMPLETEDPHASE3
903 participants
INTERVENTIONAL
Started: Mar 1, 2007
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis
NCT00307437COMPLETEDPHASE3
1.23K participants
INTERVENTIONAL
Birmingham, United States +61 more
Started: May 1, 2005
Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab)
NCT04744363COMPLETEDPHASE1
294 participants
INTERVENTIONAL
Brisbane, Australia +3 more
Started: May 25, 2021
Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy Subjects
NCT04371185COMPLETEDPHASE1
270 participants
INTERVENTIONAL
Jilin, China
Started: Aug 8, 2020
Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis
NCT04930042COMPLETEDPHASE3
581 participants
INTERVENTIONAL
Tallinn, Estonia +29 more
Started: Jun 3, 2021
A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis
NCT01008995COMPLETEDPHASE3
322 participants
INTERVENTIONAL
Beijing, China +8 more
Started: Oct 1, 2009
A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis
NCT04673786COMPLETEDPHASE3
509 participants
INTERVENTIONAL
Tartu, Estonia
Started: Jan 11, 2021
A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis
NCT00267969COMPLETEDPHASE3
766 participants
INTERVENTIONAL
Phoenix, United States +41 more
Started: Dec 1, 2005
A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis
NCT00320216COMPLETEDPHASE2
320 participants
INTERVENTIONAL
Started: Nov 1, 2003
The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment
NCT01511315COMPLETEDPHASE4
36 participants
INTERVENTIONAL
San Francisco, United States
Started: Mar 1, 2012
A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206)
NCT01276847COMPLETEDPHASE1
40 participants
INTERVENTIONAL
Started: Mar 1, 2011
An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age
NCT02698475COMPLETEDPHASE3
44 participants
INTERVENTIONAL
San Diego, United States +30 more
Started: May 1, 2016
Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis
NCT04728360COMPLETEDPHASE3
556 participants
INTERVENTIONAL
Hangzhou, China
Started: Jul 6, 2021
A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate
NCT01059773COMPLETEDPHASE4
490 participants
INTERVENTIONAL
Vienna, Austria +75 more
Started: Oct 1, 2009
A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
NCT04761627COMPLETEDPHASE3
494 participants
INTERVENTIONAL
Hot Springs, United States +87 more
Started: Mar 24, 2021
Showing 20 of 98 total trials